London, UK – [Date of Publication] – The landscape of obesity clinical trials is undergoing a seismic shift, driven by the remarkable efficacy of Glucagon-Like Peptide-1 (GLP-1) receptor agonists. As pharmaceutical giants like Novo Nordisk and Eli Lilly accelerate the development and deployment of these groundbreaking therapies, the imperative for comprehensive and scientifically rigorous data collection has never been greater. In this high-stakes environment, ICON plc, a leading contract research organization (CRO), has unveiled a pragmatic and scalable Dual-energy X-ray Absorptiometry (DXA) imaging strategy designed to overcome inherent logistical challenges and ensure the integrity of crucial body composition data. This innovative approach promises to prevent "silent attrition" – the loss of valuable participant data due to technical limitations – and bolster the scientific validity and operational efficiency of global obesity trials.
The burgeoning success of GLP-1 therapies, exemplified by semaglutide and tirzepatide, has spurred an unprecedented surge in large-scale, multi-site international clinical trials. These studies, often enrolling thousands of participants across hundreds of global locations, are designed to definitively establish the efficacy and safety of these transformative treatments. Companies are fiercely competing for eligible participants, intensifying the pressure to recruit rapidly, maintain high retention rates, and, crucially, maximize data capture from every individual enrolled. It is within this demanding context that ICON’s DXA solution emerges as a critical enabler of success.
The Escalating Stakes: GLP-1 Therapies and the Data Imperative
The current era of obesity treatment is being defined by the transformative potential of GLP-1 receptor agonists. These drugs, initially developed for diabetes management, have demonstrated remarkable efficacy in promoting significant and sustained weight loss, offering a new paradigm for addressing the global obesity epidemic. The clinical trial programs supporting these therapies are consequently scaling at an unprecedented pace.
Eli Lilly’s SURMOUNT-1 study, a landmark trial for tirzepatide, enrolled over 2,500 participants to showcase the drug’s efficacy in weight management. Similarly, Novo Nordisk’s STEP 1 trial, evaluating semaglutide, enlisted nearly 2,000 patients. Both of these pivotal studies, and many others in the pipeline, incorporated whole-body DXA imaging as a sub-study to meticulously assess changes in body composition. This detailed analysis goes beyond mere weight reduction, seeking to differentiate between fat mass, lean mass, and bone mineral density, providing a more nuanced understanding of treatment outcomes.
The sheer scale of these global trials presents significant logistical hurdles. Coordinating data collection across numerous sites, each with its own equipment and personnel, demands robust standardization and meticulous oversight. Furthermore, the intense competition for participants means that any potential for data loss, however small, can have a disproportionate impact on the overall study outcomes. When an estimated 10-15% of carefully recruited and engaged participants are at risk of yielding incomplete data due to imaging challenges, the implications for scientific integrity and trial timelines are substantial.
In this environment, imaging data is not merely a protocol requirement; it transforms into a critical component of participant retention and data completeness. A participant who undergoes screening, enrollment, and treatment, but whose imaging data cannot be fully analyzed, is effectively lost to the study, diminishing the power of the collected evidence.
The DXA Dilemma: Navigating Body Size Limitations
DXA scans have become a cornerstone of obesity clinical trials due to their established advantages: they are relatively fast, non-invasive, and offer a comfortable experience for participants. Crucially, DXA excels at differentiating between fat, bone, and lean mass. Its particular value in obesity research lies in its ability to assess visceral fat, the metabolically active fat stored deep within the abdominal cavity, which is strongly linked to an increased risk of cardiovascular disease and other metabolic complications.
However, a significant limitation of DXA technology, especially in the context of rising obesity prevalence, is that the machines are not inherently designed to accommodate participants with larger body sizes. Standard DXA protocols typically involve positioning participants on an offset, allowing for the capture of the full torso and limbs on one side. The data from the limbs is then often mirrored to provide an estimated dataset for the opposite side.
For a notable proportion of participants – estimated to be between 10% and 15% – their torso size may exceed the imaging field of view even with standard offset positioning. This inability to fully capture the torso data renders the machine incapable of performing accurate visceral fat calculations. This technical constraint creates a dual threat: it compromises the scientific integrity of the study by introducing missing data points, and it can lead to the exclusion of participants from the analysis, negatively impacting retention and potentially biasing results.
ICON’s Ingenious Solution: Maximizing Data Capture with Pragmatic Adjustments
Recognizing the escalating risk of data loss tied to the inherent limitations of DXA machines, ICON developed and implemented a proactive and scalable imaging strategy. This approach focuses on making small, yet impactful, adjustments to scan techniques, thereby enabling the capture of complete data for virtually all participants, regardless of their body size.
ICON’s strategy hinges on two primary tailored techniques, meticulously designed to ensure that the entire torso and relevant limb data are captured within the DXA scanner’s field of view:
-
Modified Hand Positioning: In standard DXA protocols, participants are typically instructed to place their hands in a specific position, often resting on their hips or above their head. For individuals with larger torsos, this standard positioning can inadvertently obstruct the necessary imaging area. ICON’s modified hand positioning technique involves instructing participants to place their hands slightly forward and away from their torso, creating more space within the scanner’s field of view to capture the full abdominal region. This simple adjustment directly addresses the primary challenge of torso truncation.
-
Dual-Scan Workflow with Centralized Review: For participants where even the modified hand positioning may not fully resolve the issue, or as a robust quality control measure, ICON implemented a dual-scan workflow. In this scenario, two scans are performed consecutively. The first scan captures as much of the torso as possible. The second scan is then performed, often with a slight adjustment in the participant’s position or the scanner’s angle, to capture the remaining portion of the torso. This dual-scan approach ensures that all necessary anatomical areas are imaged.
To guarantee the consistent application of these techniques across a global network of potentially hundreds of sites, ICON’s dedicated Medical Imaging and Cardiac Safety (IMC) team provided comprehensive training and detailed imaging manuals. These resources equipped site personnel with the precise instructions and best practices required for successful implementation.
Furthermore, a critical element of ICON’s strategy is the centralization of all imaging data. This allows for expert review and validation by a specialized team. These specialists meticulously analyze, validate, and merge the data from the dual scans, ensuring the highest levels of accuracy and consistency. This centralized review process not only preserves the integrity of the data but also enhances operational efficiency by streamlining the data management workflow.
Future-Proofing Obesity Imaging: Beyond Weight Loss to Quality of Loss
As obesity trials continue to evolve, the focus is shifting from merely quantifying weight loss to assessing the quality of that loss. This involves distinguishing between the reduction of fat mass and lean mass, and critically, understanding the changes in different types of fat, such as subcutaneous fat (under the skin) versus visceral fat (deep within the abdomen). The long-term health impacts of obesity therapies are intrinsically linked to these nuanced changes in body composition.
While Magnetic Resonance Imaging (MRI) offers superior resolution for differentiating between fat and muscle tissue, and can precisely quantify subcutaneous, intramuscular, and visceral fats while excluding organs and major blood vessels from muscle tissue analysis, it is often prohibitively expensive and complex for large-scale, multi-site trials. MRI is typically reserved for smaller subgroups or early-phase studies.
DXA, despite its limitations with extreme body sizes, remains the most feasible and cost-effective modality for large-scale obesity trials. It provides rapid and efficient scans that quantify the torso, limbs, and head, and importantly, can separate visceral fat from subcutaneous fat within the abdomen. The ability to accurately identify visceral fat is paramount, given its strong association with major adverse cardiovascular events (MACE). The innovations and insights supported by these distinctions are only achievable with high-quality, complete imaging data.
ICON’s adapted DXA strategy ensures that this vital imaging modality can be effectively implemented across diverse participant populations. By circumventing the issue of incomplete scans, this approach proactively combats the "silent attrition" of participants, thereby safeguarding the integrity of the study’s findings. This innovative imaging solution complements the multi-level, multi-channel recruitment and engagement strategies that are essential for combating high dropout rates in obesity trials. By ensuring data completeness, ICON’s approach directly supports trial timelines and reinforces the reliability of the collected evidence.
Outcome: Unlocking the Full Value of Complete Data
The implementation of ICON’s scalable DXA scan technique directly translates into the ability to perform complete visceral fat analysis for every participant. This capability is transformative for sponsors of obesity trials, allowing them to avoid data loss from an estimated 10-15% of their participant cohorts. This not only preserves the scientific integrity of their groundbreaking research but also protects their significant investments in operational timelines and budgets.
In the fiercely competitive landscape of obesity clinical trials, where participant recruitment is a hard-won battle and retention is a paramount concern, proactive and intelligent imaging design represents a strategic advantage. ICON’s commitment to innovation in medical imaging ensures that sponsors can achieve the highest levels of data integrity, leading to more robust and meaningful outcomes.
To learn more about how obesity trials are scaling with GLP-1 therapies and how ICON’s innovative imaging solutions can maximize your data capture for unparalleled data integrity and retention, please connect with us.
[Optional: If there was a downloadable document mentioned in the original source, it could be linked here with a brief description.]
About the Author
